These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22130732)

  • 1. Theoretical considerations of target-mediated drug disposition models: simplifications and approximations.
    Ma P
    Pharm Res; 2012 Mar; 29(3):866-82. PubMed ID: 22130732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approximations of the target-mediated drug disposition model and identifiability of model parameters.
    Gibiansky L; Gibiansky E; Kakkar T; Ma P
    J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):573-91. PubMed ID: 19005743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target-mediated drug disposition model for drugs that bind to more than one target.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations.
    Koch G; Jusko WJ; Schropp J
    J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):17-26. PubMed ID: 28074395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity conditions of approximations for a target-mediated drug disposition model: A novel first-order approximation and its comparison to other approximations.
    Byun JH; Jeon HS; Yun HY; Kim JK
    PLoS Comput Biol; 2024 Apr; 20(4):e1012066. PubMed ID: 38656966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.
    Koch G; Jusko WJ; Schropp J
    J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):27-42. PubMed ID: 28074396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target-mediated drug disposition model and its approximations for antibody-drug conjugates.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):35-47. PubMed ID: 24322877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.
    Lavezzi SM; Mezzalana E; Zamuner S; De Nicolao G; Ma P; Simeoni M
    J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):787-802. PubMed ID: 30415351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model.
    Yan X; Krzyzanski W
    J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):141-6. PubMed ID: 22215144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site.
    Gibiansky L; Ng CM; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2024 Dec; 51(6):703-720. PubMed ID: 38639818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations.
    Eudy RJ; Riggs MM; Gastonguay MR
    AAPS J; 2015 Sep; 17(5):1280-4. PubMed ID: 26077506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of target-mediated drug disposition.
    Peletier LA; Gabrielsson J
    Eur J Pharm Sci; 2009 Dec; 38(5):445-64. PubMed ID: 19786099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification.
    Peletier LA; Gabrielsson J
    J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):429-51. PubMed ID: 22851162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mathematical description of drug-target interactions: application to biologics that bind to targets with two binding sites.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2018 Feb; 45(1):23-34. PubMed ID: 28918570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2024 Aug; 51(4):307-317. PubMed ID: 38700803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model.
    Xin Y; Xiang H; Jin D; Theil FP; Joshi A; Damico-Beyer LA; Bai S
    J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):217-26. PubMed ID: 22382554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens.
    Yan X; Ruixo JJP; Krzyzanski W
    AAPS J; 2020 Jan; 22(2):30. PubMed ID: 31950308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.
    Gibiansky L; Gibiansky E
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):803-12. PubMed ID: 19505189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical approximations of sensitivities of steady state predictions to errors in parameter estimation: II. Michaelis-Menten kinetics.
    Gonda I
    J Pharmacokinet Biopharm; 1984 Oct; 12(5):525-34. PubMed ID: 6520746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.